RxDoctor Payments DataLook up a doctor →

Steven Rosen, MD

Pain Management · Jenkintown, PANPI 1144294323

Payments from drug & device makers

$430,341in general payments, 2019–2025

Across 586 payments — averaging $734.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$330K
  • Boston Scientific$67K
  • Biotronik Inc.$13K
  • Flowonix Medical Incorporated$9K
  • Medtronic$7K
  • Spinal Simplicity, LLC$2K
  • plus $4K from 19 others
$43,155in research payments, 2019–2025

Across 23 payments — averaging $1876.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Flowonix Medical Incorporated$33K
  • Saluda Medical Americas, Inc.$11K

What the payments were for

  • Consulting fees$51,08562%
  • Speaking & faculty fees$11,90014%
  • Travel & lodging$8,26510%
  • Food & beverage$9,46312%
  • Education$1,5162%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain management providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$491,383
Medicare patients
339
Services billed
22,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl11$12,987
Lidocaine29$5,406
Oxycodone Hcl296$5,136
Tizanidine Hcl99$2,209
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen110$1,382
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,314
Pregabalin49$1,177
Gabapentin82$1,124
Hydromorphone Hcl71$1,063
Fentanyl18$997
Methylprednisolone95$703
Duloxetine Hcl37$697
Morphine Sulfate29$667
Celecoxib15$516
Tramadol Hcl102$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$92$12,98711 claims
Hikma Pharmaceuticals USAMorphine Sulfate$63$66729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other pain management in Jenkintown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →